• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    8/2/23 1:31:09 PM ET
    $ADMP
    $AHI
    $APLT
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $ADMP alert in real time by email

    Gainers

    • Trxade Health (NASDAQ:MEDS) shares moved upwards by 63.3% to $10.96 during Wednesday's regular session. As of 13:30 EST, Trxade Health's stock is trading at a volume of 8.0 million, which is 1606.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.4 million.
    • Advanced Health (NASDAQ:AHI) shares rose 33.98% to $4.14. As of 13:30 EST, this security is trading at a volume of 29.3 million shares, making up 1573.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $28.9 million.
    • Applied Therapeutics (NASDAQ:APLT) shares moved upwards by 20.92% to $2.07. As of 13:30 EST, this security is trading at a volume of 1.2 million shares, making up 519.5% of its average full-day volume over the last 100 days. The company's market cap stands at $119.6 million.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) shares rose 16.78% to $0.7. Trading volume for TC BioPharm (Holdings)'s stock is 976.1K as of 13:30 EST. This is 174.9% of its average full-day volume over the last 100 days. The company's market cap stands at $3.2 million.
    • TRACON Pharma (NASDAQ:TCON) stock rose 13.72% to $0.37. The current volume of 2.1 million shares is 829.3% of TRACON Pharma's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $9.7 million.
    • Frequency Therapeutics (NASDAQ:FREQ) stock moved upwards by 13.33% to $0.57. As of 13:30 EST, Frequency Therapeutics's stock is trading at a volume of 1.2 million, which is 75.2% of its average full-day volume over the last 100 days. The company's market cap stands at $21.0 million.

    Losers

    • Adamis Pharmaceuticals (NASDAQ:ADMP) stock declined by 63.4% to $1.46 during Wednesday's regular session. As of 13:30 EST, this security is trading at a volume of 21.6 million shares, making up 4550.7% of its average full-day volume over the last 100 days. The company's market cap stands at $4.0 million.
    • Aptevo Therapeutics (NASDAQ:APVO) shares decreased by 37.19% to $0.62. Trading volume for Aptevo Therapeutics's stock is 2.1 million as of 13:30 EST. This is 1205.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $4.6 million.
    • Biophytis (NASDAQ:BPTS) shares declined by 23.18% to $1.33. As of 13:30 EST, this security is trading at a volume of 220.5K shares, making up 81.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.7 million.
    • Nevro (NYSE:NVRO) shares fell 20.76% to $19.55. Trading volume for Nevro's stock is 1.3 million as of 13:30 EST. This is 235.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $700.2 million. The company's, Q2 earnings came out yesterday.
    • SmileDirectClub (NASDAQ:SDC) shares declined by 18.01% to $0.89. Trading volume for SmileDirectClub's stock is 6.7 million as of 13:30 EST. This is 389.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $118.3 million.
    • Bio-Path Hldgs (NASDAQ:BPTH) stock declined by 15.3% to $0.83. As of 13:30 EST, Bio-Path Hldgs's stock is trading at a volume of 362.7K, which is 321.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $6.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMP
    $AHI
    $APLT
    $APVO

    CompanyDatePrice TargetRatingAnalyst
    Applied Therapeutics Inc.
    $APLT
    12/12/2025Outperform → Neutral
    Robert W. Baird
    Applied Therapeutics Inc.
    $APLT
    12/3/2025$1.00Outperform → Market Perform
    Leerink Partners
    Nevro Corp.
    $NVRO
    2/10/2025$4.50 → $5.85Underperform → Hold
    Jefferies
    Nevro Corp.
    $NVRO
    2/7/2025$6.00 → $5.85Neutral → Overweight
    Piper Sandler
    Applied Therapeutics Inc.
    $APLT
    12/23/2024Outperform → Mkt Perform
    William Blair
    Nevro Corp.
    $NVRO
    12/3/2024$5.00Equal Weight
    Wells Fargo
    Applied Therapeutics Inc.
    $APLT
    12/2/2024$13.00 → $2.00Buy → Neutral
    UBS
    Nevro Corp.
    $NVRO
    12/2/2024$9.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $ADMP
    $AHI
    $APLT
    $APVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZIMHI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug ZIMHI (ORIG-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 10/15/2021. Application Category: NDA, Application Number: 212854, Application Classification: Type 5 - New Formulation or New Manufacturer

    10/18/21 11:55:40 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SYMJEPI issued to ADAMIS PHARMS CORP

    Submission status for ADAMIS PHARMS CORP's drug SYMJEPI (SUPPL-12) with active ingredient EPINEPHRINE has changed to 'Approval' on 06/29/2021. Application Category: NDA, Application Number: 207534, Application Classification: Labeling

    6/30/21 5:11:48 AM ET
    $ADMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHI
    $APLT
    $APVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Grant Grady Iii bought $20,134 worth of shares (13,513 units at $1.49), increasing direct ownership by 1,351,300% to 13,514 units (SEC Form 4)

    4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

    11/12/25 4:33:00 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kanter Stacy J. bought $65,367 worth of shares (30,000 units at $2.18), increasing direct ownership by 91% to 63,000 units (SEC Form 4)

    4 - Applied Therapeutics Inc. (0001697532) (Issuer)

    12/5/23 7:03:09 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHI
    $APLT
    $APVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kanter Stacy J. returned 22,500 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

    2/4/26 11:17:54 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Hooks Corwin Dale was granted 312,500 shares and returned 862,500 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

    2/3/26 7:16:05 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Chinoporos Constantine was granted 437,500 shares and returned 1,000,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

    2/3/26 7:03:25 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHI
    $APLT
    $APVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics

    Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ:APLT, "Applied")), a clinical-stage biopharmaceutical company. Applied's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), for which there are currently no FDA approved treatment options available. "Cycle was founded with a commitment to support patients livi

    2/3/26 8:39:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics Shares Letter to Stockholders Recommending Tender of Shares Following Offer Expiration Extension

    NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company" or "Applied"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today released the following letter to stockholders regarding the pending tender offer by AT2B, Inc. ("Purchaser"), an indirect wholly owned subsidiary of Cycle Group Holdings Limited ("Cycle"). January 29, 2026 Dear Applied Therapeutics Stockholders, As announced on December 11, 2025, we entered into a definitive agreement (the "Merger Agreement") with Cycle, a United Kingdom-based company focused on rare genetic conditions in metabolic, immunology, urology and onc

    1/29/26 8:15:13 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cycle Pharmaceuticals to Acquire Applied Therapeutics

    NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT, "Applied")), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced a definitive agreement for Cycle Group Holdings Limited ("Cycle") to acquire Applied Therapeutics. Applied Therapeutics is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases. Applied's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Gala

    12/11/25 5:25:00 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHI
    $APLT
    $APVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Applied Therapeutics downgraded by Robert W. Baird

    Robert W. Baird downgraded Applied Therapeutics from Outperform to Neutral

    12/12/25 9:22:39 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Applied Therapeutics from Outperform to Market Perform and set a new price target of $1.00

    12/3/25 8:27:30 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nevro upgraded by Jefferies with a new price target

    Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously

    2/10/25 7:02:54 AM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    $ADMP
    $AHI
    $APLT
    $APVO
    SEC Filings

    View All

    SEC Form 10-K filed by Aptevo Therapeutics Inc.

    10-K - Aptevo Therapeutics Inc. (0001671584) (Filer)

    3/26/26 4:15:24 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aptevo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)

    3/26/26 4:05:07 PM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 1-A filed by Bio-Path Holdings Inc.

    1-A - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

    3/25/26 2:24:02 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHI
    $APLT
    $APVO
    Leadership Updates

    Live Leadership Updates

    View All

    Applied Therapeutics Reports Third Quarter 2025 Financial Results

    –   Update on regulatory strategy for govorestat for the treatment of CMT-SORD following receipt of Type C meeting minutes –   Meeting scheduled with the FDA in 4Q 2025 to discuss govorestat for the treatment of Classic Galactosemia –   New data on govorestat for the treatment of PMM2-CDG published in JIMD and presented at the 2025 ASHG Annual Meeting –   Announces Board of Directors Leadership Transition NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today reported financial results for the third quarter ended September 30

    11/13/25 7:00:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

    NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part of the Company's executive leadership team and will be responsible for leading Applied's global regulatory strategy. Dr. Baumgartner joins Applied as an accomplished global drug development leader with over 35 years of experience in senior regulatory, clinical development, and medical affairs roles. He has held a diverse set of leadership roles over the course of his career, notably

    3/19/25 7:00:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

    SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

    1/21/25 8:15:00 AM ET
    $MEDS
    $OGEN
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ADMP
    $AHI
    $APLT
    $APVO
    Financials

    Live finance-specific insights

    View All

    Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics

    Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ:APLT, "Applied")), a clinical-stage biopharmaceutical company. Applied's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), for which there are currently no FDA approved treatment options available. "Cycle was founded with a commitment to support patients livi

    2/3/26 8:39:00 AM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings Provides Clinical and Operational Update

    HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An archived webcast of the event can be accessed here. "Our business model centers around generating new drug candidates from our DNAbilize® platform and licensing them for final development and commercialization with partners that have expertise and scale to successfully bring them to market," sa

    6/3/25 7:00:00 AM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

    HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, www.biopathho

    5/22/25 4:30:00 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADMP
    $AHI
    $APLT
    $APVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nevro Corp.

    SC 13G - NEVRO CORP (0001444380) (Subject)

    12/4/24 4:27:18 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

    SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

    11/14/24 5:47:55 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care